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November 21, 2014 
DISCLAIMER 
• Thoughts presented here regarding new policy / 
regulatory issues are preliminary and do not represent 
finalized FDA policy 
 
• FDA cannot comment on specific investigations. 
ISSUES 
• FDA is seeing more researchers apply 
discoveries in the clinic. 
• Most academic researchers do not understand 
their obligations under the IDE regulation. 
• Most academic institutions do not provide 
adequate regulatory support. 
In Vitro Diagnostics (IVDs)  
• In vitro diagnostic devices include “…those reagents, instruments, and 
systems intended for use in the diagnosis of disease or other 
conditions, including a determination of the state of health, in order to 
cure, mitigate, treat, or prevent disease or its sequelae. Such products 
are intended for use in the collection, preparation, and examination of 
specimens taken from the human body. These products are devices as 





• Intended use:  How will the device will be used in the therapeutic 
product trial? Encompasses: 
– Analyte to be detected 
– Type of result (quantitative, semi-quantitative, qualitative) 
– Specimen type(s) 
– Disease to be screened, monitored, treated, or diagnosed 












MammaPrint® is a qualitative in vitro diagnostic test service, performed in a single 
laboratory, using the gene expression profile of fresh frozen breast cancer 
tissue samples to assess a patients' risk for distant metastasis. 
The test is performed for breast cancer patients who are less than 61 years old, 
with Stage I or Stage II disease, with tumor size <= 5.0 cm and who are lymph 
node negative.  The MammaPrint® result is indicated for use by physicians as 








 What assay measures, how to use results 
Intended Use  
Types of studies depend on IU claims;  
Less dependent on the technology or assay format 
Things that are or can be medical 
devices include: 
• Instrumentation 
• In vitro diagnostic kits 
• Reagents used for laboratory 
testing 
• Some apps 
• Software 
• Algorithms 
Medical devices are subject to regulatory requirements 
even though they may only be investigational.  
Some common misconceptions: 
• It is not a test, it is a process. 
• It is not an IVD if it is in the research and development 
stage. 
• It is not an IVD if I don’t plan to market the test. 
• The IDE regulation does not apply if I don’t plan to 
market the test. 
• I have CLIA certification, so I don’t need to worry about 
the IDE regulation. 
• I can never generate enough data to submit an IDE. 









Protect human subjects 
PMA or 510k 
Assure safety and 
effectiveness 
What is an investigation? 
• Investigation means a clinical investigation or research 
involving one or more subjects to determine the safety or 
effectiveness of a device. 
Definition of “Subject” for Investigations 
• Subject means a human who participates in an 
investigation, either as an individual on whom or 
on whose specimen an investigational device is 
used or as a control. A subject may be in normal 
health or may have a medical condition or 
disease. 
 
What is an Investigational Device? 
• Investigational device means a device…that is the object of 
an investigation. 
 
• An investigational IVD is not legally marketed for the intended 
use or indication for use identified in that study, whether or not 
it has been previously cleared or approved for a separate 
intended use. 
 
• Important to distinguish from off-label use or practice of 
medicine. 
 
• Investigational use requires an exemption from premarket 
approval requirements for new drugs and devices. 
 
IVDs: Companion Diagnostics 
• Companion diagnostics are IVDs 
 
• An IVD companion diagnostic device is an in vitro diagnostic device 
that provides information that is essential for the safe and effective 
use of a corresponding therapeutic product. 
– Note: it is important to recognize, for example, that when a validated prognostic 
test is used to select patients for treatment, the ability to select patients who are 
expected to benefit from the treatment is an investigational use for which the test 
has not been validated until the investigational therapeutic product has 
demonstrated safety and efficacy in the test-selected population. 
• Drugs and their companion tests refer to each other in their labels. 










excluded from trial 
and/or receive SOC 
Test result influences treatment. 
placebo or 
comparator 
MARKER USED FOR STRATIFICATION 
investigational IVD 









Test result does not influence treatment. 
Other trial designs 
• Adaptive 
 
• Basket trials 
IDE Regulation (21 CFR 812) 
• “…purpose…is to encourage, to the extent consistent with the 
protection of public health and safety and with ethical 
standards, the discovery and development of useful devices 
intended for human use, and to that end to maintain optimum 
freedom for scientific investigators in their pursuit of this purpose.” 
• An IDE is a regulatory submission that permits clinical 
investigation of devices/IVDs. 
• An approved IDE permits a device to be shipped lawfully for the 
purpose of conducting investigations of the device without 
complying with other requirements of the Food, Drug, and 
Cosmetic Act (Act) that would apply to devices in commercial 
distribution.  
• Focused on risk 
• Delegated responsibilities 
IDE approval aims to ensure that: 
• Risks are outweighed by anticipated benefits to 
subjects and importance of knowledge to be 
gained. 
• Informed consent is adequate. 
• Investigation is scientifically sound. 
 
      All Device Investigations 
Studies Exempt 
from the IDE 
Regulation 







IDE: A Risk-Based Approach to IVD 
Regulation 
• IDE requirements depend on the risk of the test use to 
study subjects in the investigation. 
• For IVD tests, it is important to think about the risks 
associated with erroneous test results.  What would 
happen if the test results are wrong? 
– False positive or false negative results mean that a patient may 
be diverted from therapeutic options which may be more 
beneficial to them. 
– Patients may be subject to adverse events from the 
investigational trial when they are not intended to be the subject 
of the investigation. 19 
IDE Exempt 
• 812.2(c)(3): A diagnostic device [is exempt], if the sponsor complies 
with applicable requirements in 809.10(c) [labeling] and if the 
testing: 
– (i) Is noninvasive, 
– (ii) Does not require an invasive sampling procedure that presents 
significant risk, 
– (iii) Does not by design or intention introduce energy into a subject, and 
– (iv) Is not used as a diagnostic procedure without confirmation of the 
diagnosis by another, medically established diagnostic product or 
procedure. 
• Example: Use of an in vitro diagnostic in a retrospective study of 
accrued specimens (without return of results). 
• Depends on interpretation of “medically established”. 
Nonsignificant risk (NSR) 
• Does not meet the definition of significant risk (SR) in 812.3(m). 
• Abbreviated requirements: 
– Labeling (812.5) 
– IRB approval 
– Informed consent (part 50) 
– Monitoring (812.46) 
– Records (812.140) and reporting (812.150) (sponsor and 
investigator) 
– Prohibition against promotion and other practices (812.7.) 
• No IDE application to the FDA required. Meeting the abbreviated 
requirements (including IRB approval!) means that you have an 
approved application for an IDE. 
• Example: Use of an investigational IVD test to stratify patients for 
treatment in a clinical trial. 
Significant Risk (SR) 
• Significant risk device (812.3(m)) means an investigational device 
that: 
– 1) Is intended as an implant and presents a potential for serious 
risk to the health, safety, or welfare of a subject; 
– (2) Is purported or represented to be for a use in supporting or 
sustaining human life and presents a potential for serious risk to 
the health, safety, or welfare of a subject; 
– (3) Is for a use of substantial importance in diagnosing, curing, 
mitigating, or treating disease, or otherwise preventing 
impairment of human health and presents a potential for serious 
risk to the health, safety, or welfare of a subject; or 
– (4) Otherwise presents a potential for serious risk to the health, 
safety, or welfare of a subject. 
• Example: Use of an investigational in vitro diagnostic test to select 
patients for a clinical trial. 
• Accrual by test result 
• Rx assignment 
• Safety signal for Rx 
• Convenience biomarker 
• Weak/conflicting info on 
biomarker effect 
• Invasive sampling 
• All-comers accrual 
• Stratification 
• No “known effective” Rx 
• Targeted biomarker 
• Strong biomarker effect 
known 
• Non-invasive sampling 
BALANCED APPROACH TO IVD RISK 
Context and effect of an incorrect test result 
More Risk Less Risk Cancer is a 
serious disease.  
Any effect on a 
treatment decision 
arising from IVD 
use poses 
significant risk. 
Cancer is a 
serious disease.  
Large and unmet 
medical need 
makes any IVD 
risk minor. 
Assessing Risk 
1. Will use of the investigational test results lead to some trial subjects 
foregoing or delaying a treatment that is known to be effective? 
2. Will use of the investigational test results expose trial subjects to 
safety risks (e.g., adverse events from the experimental therapy) 
that (in some “net” sense) exceed the risks encountered with 
control therapies or non-trial standard of care? 
3. Is it likely, based on a priori information about the investigational 
therapy, that incorrect test results would degrade the safety or 
efficacy of subjects’ treatment? 
4. Does specimen acquisition, done for investigational testing and 
outside the standard of care, require an invasive sampling 
procedure that presents significant risk? 
Risk in Investigations Using Genetic 
Testing 
• What are the clinical indications for testing? 
• Are the results confirmed by an acceptable technique? What 
is an acceptable technique? 
• Are results returned? 
• Will results be placed in the medical record? 
• How are results communicated to the treating physician? 
• What are the risks of an incorrect test result? 
– What clinical actions might be taken based on test results? 
– How urgent are the results? 
 
Some Features with Lesser Relevance for 
IVD Risk Determination 
• Size of trial 
• Access to “other trials” 
• Clinical trial phase 
 
Risk in Ongoing Trials 
• Risk can change during the course of a trial. 
– Adaptive trials 
– Protocol changes 
– New information (DSMB review) 
 
• If IVD use becomes SR in the middle of a trial, an IDE is 
required. 
 
• Ongoing surveillance is recommended. 
Researchers have identified a biomarker that they hypothesize will 
predict response to a new drug for colorectal cancer. They develop 
an IVD to detect the biomarker, and design a clinical trial in which 
only those patients that are positive for the biomarker will receive 
the drug. Other inclusion criteria specify that the patients have 
exhausted all other lines of therapy. 
 
– What is the risk of the use of IVD in the trial? 
– If an earlier trial of the drug identified potentially serious or life-
threatening toxicities, would your risk assessment change? 
Example 1 
 
– Initial decision: NSR. Although the IVD is used for 
selection, there are no known effective therapies 
remaining for patients. Therefore, false results do not pose 
added risk to patients. 
 
– Modified decision: SR. Although there are no known 
effective therapies remaining, side effects from the drug 
may unreasonably degrade quality of life or lead to death 
earlier than would be predicted from the normal course of 
the disease. False positive patients would be exposed to 
these risks without any reasonable expectation of benefit. 
Example 1 
Researchers have developed a test to detect a biomarker in bone marrow, 
and design a clinical trial to use the IVD to select patients with pancreatic 
cancer to receive a drug that is approved for use in prostate cancer. To 
enter the trial, patients must have additional bone marrow biopsies, and 
have not received any prior lines of therapy. The toxicities of the drug are 
well-understood and can be mitigated with appropriate monitoring. 
 
– What is the risk of the use of IVD in the trial? 
– What if an earlier trial suggested that marker-positive patients with 
pancreatic cancer could respond to the new drug? 
Example 2 
 
– Initial decision: SR. The IVD is used for selection. False results will 
divert patients from standard of care or known effective therapies. 
 
– Modified decision: NSR. Given preliminary indications that the 
biomarker predicts response to the drug, test-positive patients have a 
reasonable expectation of benefit. False results can be mitigated by 
monitoring. While extra bone marrow biopsies are invasive, they may 
not pose high enough risk to qualify the study as significant risk. 
 
– In real life, this scenario should be discussed with FDA. 
Example 2 
Delegated Responsibilities and Risk Determination 
• Sponsor makes initial determination and 








• FDA can help; FDA determination is final 
1. Are one or more IVD devices being used in this study to select patients for 
treatment? 
2. Is the device investigational? 
a. Has the device been cleared or approved by the FDA? 
b. If the IVD has been cleared or approved, is it being put to a new use in 
the trial? 
3. What are the risks of IVD use in the study? 
a. Does specimen collection present a risk? 
b. What are the risks of inaccurate results? 
i. Is the IVD used for enrollment or assignment to an arm? 
ii. Will the IVD be used for patient monitoring or adjusting dosage? 
iii. Are the benefits of treatment greater than the risks of an inaccurate 
IVD result? 
4. Will results from the IVD device be supported by use of an independent 
confirmatory test? 
5. Does the informed consent cover the use of the investigational IVD? 
Some Recommended Questions for IRBs 
FDA Policy for CDx Trials 
 
• SR IVD: An IDE is required for an investigation even if there is an 
IND for use of the drug, or if the drug is IND exempt. 
 
• NSR IVD: An IDE is not required, and cannot be accepted for 
review. 
– The trial still has to comply with the abbreviated requirements. 
– Some information on the test may be requested in the IND. 
– A presubmission with CDRH is recommended. 
 
• A trial may not proceed until it has received IND and/or IDE approval 
AND IRB approval. 
Common Problems 
• Failure to recognize that the biomarker test is an investigational 
medical device. 
• Expectation that compliance with IND regulation is sufficient to 
satisfy requirements under the IDE regulation. 
• Risk misdetermination. If the IRB agrees the device is NSR, 
FDA will never see a submission, and will be unaware of the 
trial. 
• Change in risk during course of trial. 
Presubmission Process 
– You can meet with the FDA for nonbinding discussions and 
advice: 
• before conducting studies, including clinical trials 
• before submitting a marketing application 
 
– This is an opportunity to address new scientific and regulatory 
issues. 
 
– Particularly important when developing new technologies. 
 
– The earlier the better! 
 





– IRB Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of 
Research Sites, and the Determination of Whether an IND/IDE is Needed. 
http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM328855.pdf 
– FDA Decisions for Investigational Device Exemption (IDE) Clinical Investigations. 
http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/Guid
anceDocuments/UCM279107.pdf 
– Significant Risk and Nonsignificant Risk Medical Device Studies. 
http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126418.pdf 
– Others at www.fda.gov 
• Device Advice 
– http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/default.htm  
• CDRH Learn (including information about sponsor responsibilities, 
investigator responsibilities, IRBs, and the Bioresearch Monitoring 
Program) 
– http://www.fda.gov/Training/CDRHLearn/default.htm  
Other FDA efforts 
• Educational –  
– Conferences 
– Discussion with IRBs, academic investigators, 
and institutions 
• Work with NIH to disseminate information 
early in the granting process 
